Chugai Pharmaceutical First Quarter 2025 Earnings: Beats Expectations

Chugai Pharmaceutical (TSE:4519) First Quarter 2025 Results

Key Financial Results

• Revenue: JP¥288.5b (up 22% from 1Q 2024).
• Net income: JP¥97.2b (up 31% from 1Q 2024).
• Profit margin: 34% (up from 31% in 1Q 2024). The increase in margin was driven by higher revenue.
• EPS: JP¥59.09 (up from JP¥45.22 in 1Q 2024).

Our free stock report includes 1 warning sign investors should be aware of before investing in Chugai Pharmaceutical. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chugai Pharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 19%.

Looking ahead, revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Chugai Pharmaceutical you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.